ES2614803T3 - Métodos y composiciones basadas en proteína tipo 2 de la toxina Shiga - Google Patents

Métodos y composiciones basadas en proteína tipo 2 de la toxina Shiga Download PDF

Info

Publication number
ES2614803T3
ES2614803T3 ES10733840.2T ES10733840T ES2614803T3 ES 2614803 T3 ES2614803 T3 ES 2614803T3 ES 10733840 T ES10733840 T ES 10733840T ES 2614803 T3 ES2614803 T3 ES 2614803T3
Authority
ES
Spain
Prior art keywords
stx2
seq
stx1
toxin
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10733840.2T
Other languages
English (en)
Spanish (es)
Inventor
Alison O'brien
Angela Melton-Celsa
Michael Smith
James Sinclair
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henry M. Jackson Foundation
Original Assignee
Henry M. Jackson Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henry M. Jackson Foundation filed Critical Henry M. Jackson Foundation
Application granted granted Critical
Publication of ES2614803T3 publication Critical patent/ES2614803T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • C07K16/1232—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
ES10733840.2T 2009-01-23 2010-01-21 Métodos y composiciones basadas en proteína tipo 2 de la toxina Shiga Active ES2614803T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US146892P 1999-08-02
US14689209P 2009-01-23 2009-01-23
US21008209P 2009-03-13 2009-03-13
US210082P 2009-03-13
PCT/US2010/021610 WO2010085539A1 (en) 2009-01-23 2010-01-21 Methods and compositions based on shiga toxin type 2 protein

Publications (1)

Publication Number Publication Date
ES2614803T3 true ES2614803T3 (es) 2017-06-02

Family

ID=42356196

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10733840.2T Active ES2614803T3 (es) 2009-01-23 2010-01-21 Métodos y composiciones basadas en proteína tipo 2 de la toxina Shiga

Country Status (16)

Country Link
US (2) US8969529B2 (enExample)
EP (1) EP2381954B8 (enExample)
JP (1) JP5773886B2 (enExample)
KR (1) KR101832499B1 (enExample)
CN (1) CN102292098A (enExample)
AR (1) AR075047A1 (enExample)
AU (1) AU2010206800B2 (enExample)
BR (1) BRPI1007230B1 (enExample)
CA (1) CA2748873C (enExample)
CL (1) CL2011001769A1 (enExample)
ES (1) ES2614803T3 (enExample)
MX (1) MX2011007866A (enExample)
NZ (1) NZ593926A (enExample)
PE (1) PE20120425A1 (enExample)
RU (1) RU2011126896A (enExample)
WO (1) WO2010085539A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1229045A1 (en) * 2001-02-01 2002-08-07 Institut Curie Universal carrier for targeting molecules to Gb3 receptor expressing cells
AU2007240614B2 (en) 2006-04-20 2013-09-12 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Incorporated Methods and compositions based on Shiga toxin type 1 protein
US8969529B2 (en) 2009-01-23 2015-03-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods and compositions based on shiga toxin type 2 protein
US9513287B1 (en) * 2012-09-28 2016-12-06 The United States Of America, As Represented By The Secretary Of Agriculture High affinity monoclonal antibodies for detection of shiga toxin 2
US9310368B1 (en) * 2012-09-28 2016-04-12 The United States Of America, As Represented By The Secretary Of Agriculture High affinity monoclonal antibodies for detection of Shiga toxin 2 (STX2)
CN111363047A (zh) * 2013-03-12 2020-07-03 分子模板公司 用于引起细胞内化的cd20结合免疫毒素及其使用方法
CN103343164B (zh) * 2013-06-17 2016-05-18 武汉轻工大学 产志贺毒素大肠杆菌多重pcr检测方法、试剂盒及应用
RU2573924C2 (ru) * 2013-07-11 2016-01-27 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) НЕТОКСИЧНЫЙ РЕКОМБИНАНТНЫЙ ШИГА ТОКСИН 2-ГО ТИПА (Stx2)
ES2749862T3 (es) * 2014-01-27 2020-03-24 Molecular Templates Inc Polipéptidos efectores desinmunizados de subunidad A de toxina Shiga para aplicaciones en mamíferos
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
KR102496206B1 (ko) * 2014-06-11 2023-02-06 몰레큘러 템플레이츠, 인코퍼레이션. 프로테아제-절단 저항성의 시가 독소 a 서브유닛 작동체 폴리펩티드 및 이를 포함하는 세포-표적화 분자
CN104558167B (zh) * 2014-12-26 2017-12-26 江苏省疾病预防控制中心 检测i型志贺毒素双抗夹心法酶联免疫试剂盒及其应用
WO2016126950A1 (en) 2015-02-05 2016-08-11 Molecular Templates, Inc. Multivalent cd20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN114656573B (zh) 2015-05-30 2024-09-27 分子模板公司 去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
MX2019006656A (es) 2016-12-07 2019-09-09 Molecular Templates Inc Polipeptidos efectores de la sub-unidad a de la toxina shiga andamiajes de los efectores de la toxina shiga y moleculas con direccion hacia las celulas para la conjugacion especifica del sitio.
KR102590672B1 (ko) 2017-01-25 2023-10-18 몰레큘러 템플레이츠, 인코퍼레이션. 탈면역된 시가 독소 a 서브유닛 이펙터 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
KR20200143634A (ko) 2018-04-17 2020-12-24 몰레큘러 템플레이츠, 인코퍼레이션. 탈면역된 시가 독소 a 서브유닛 스캐폴드를 포함하는 her2-표적화 분자
CN115856296B (zh) * 2022-12-16 2023-07-25 华北理工大学 抗志贺氏菌的单克隆抗体及其检测中的应用
CN120647752B (zh) * 2025-08-19 2025-10-28 中国人民解放军军事科学院军事医学研究院 一种抗ⅱ型志贺毒素的单克隆抗体及其相关产品和应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5164298A (en) 1988-06-24 1992-11-17 Hsc Research Development Corporation Verocytotoxin receptor assay
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5552144A (en) * 1992-01-22 1996-09-03 Microcarb, Inc. Immunogenic shiga-like toxin II variant mutants
US5747272A (en) 1994-02-14 1998-05-05 Henry M. Jackson Foundation For The Advancement Of Military Medicine Detection of shiga-like toxins of enterohemoragic Escherichia coli
US5968894A (en) 1994-02-22 1999-10-19 Lingwood; Clifford A. Verotoxin pharmaceutical compositions and medical treatments therewith
CA2265887A1 (en) 1996-09-10 1998-03-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Histidine-tagged shiga toxins, toxoids, and protein fusions with such toxins and toxoids, methods for the purification and preparation thereof
WO1998020903A1 (en) 1996-11-15 1998-05-22 Trustees Of Tufts College Humanized neutralizing antibodies against hemolytic uremic syndrome
US7910096B2 (en) 1996-11-15 2011-03-22 Trustees Of Tufts College Human neutralizing antibodies against hemolytic uremic syndrome
US20020160005A1 (en) * 1996-11-15 2002-10-31 Trustees Of Tufts College Human neutralizing antibodies against hemolytic urmec syndrome
US20030170248A1 (en) 1997-12-23 2003-09-11 Jeffrey R. Stinson Humanized monoclonal antibodies that protect against shiga toxin induced disease
DK1079856T3 (da) 1998-05-20 2006-12-04 Teijin Ltd Humaniserede antistoffer til genkendelse af verotoxin II samt cellelinie til produktion af samme
DE602004032143D1 (de) * 2003-07-21 2011-05-19 Intervet Int Bv Hybrid-toxine mit shiga-artigen toxin-untereinheiten, verbunden mit escherichia coli wärmeinstabilen enterotoxin-untereinheiten und vakzine daraus
JP5618453B2 (ja) 2003-11-28 2014-11-05 ナショナル リサーチ カウンシル オブ カナダ 抗癌抗体およびその使用
CA2555306A1 (en) 2004-02-06 2005-08-18 Nymox Corporation Humanized antibody
CA2458084A1 (en) 2004-03-12 2005-09-12 Dalton Chemical Laboratories Inc. Novel process for octreotide synthesis
WO2006091677A1 (en) * 2005-02-22 2006-08-31 Jean Gariepy Yeast strains expressing ribosome-inactivating protein domain and method of using same
EP1991565B1 (en) 2006-02-16 2015-01-21 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Shiga toxoid chimeric proteins
AU2007240614B2 (en) 2006-04-20 2013-09-12 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Incorporated Methods and compositions based on Shiga toxin type 1 protein
AU2007254950A1 (en) 2006-05-31 2007-12-13 Thallion Pharmaceuticals Incorporated Methods, compositions, and kits for treating Shiga toxin associated conditions
US20090258010A1 (en) 2006-05-31 2009-10-15 Thallion Pharmaceuticals, Inc. Methods, compositions, and kits for treating shiga toxin associated conditions
JP4954293B2 (ja) 2006-12-29 2012-06-13 オスプレイ・ファーマシューティカルズ・ユーエスエイ・インコーポレイテッド 改変毒素を選択および生産する方法、改変毒素を含む複合体、およびそれらの使用
US20100298238A1 (en) * 2007-10-08 2010-11-25 Rutgers, The State University Nontoxic shiga-like toxin mutant compositions and methods
CN101314616B (zh) * 2008-05-30 2011-05-11 中国人民解放军第三军医大学 肠出血性大肠杆菌o157:h7志贺毒素ⅱb表位肽及其应用
CA2736877A1 (en) * 2008-09-12 2010-03-18 Scarab Genomics, Llc Clean genome bactofection
US8969529B2 (en) 2009-01-23 2015-03-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods and compositions based on shiga toxin type 2 protein

Also Published As

Publication number Publication date
US20110318357A1 (en) 2011-12-29
AU2010206800A1 (en) 2011-07-28
WO2010085539A1 (en) 2010-07-29
NZ593926A (en) 2013-03-28
CN102292098A (zh) 2011-12-21
US8969529B2 (en) 2015-03-03
JP5773886B2 (ja) 2015-09-02
KR101832499B1 (ko) 2018-02-26
US20160243210A1 (en) 2016-08-25
EP2381954A4 (en) 2012-08-01
RU2011126896A (ru) 2013-02-27
CA2748873A1 (en) 2010-07-29
US9801931B2 (en) 2017-10-31
MX2011007866A (es) 2011-10-06
AU2010206800B2 (en) 2016-06-30
EP2381954B1 (en) 2016-11-02
KR20110119725A (ko) 2011-11-02
PE20120425A1 (es) 2012-05-03
AR075047A1 (es) 2011-03-02
EP2381954A1 (en) 2011-11-02
BRPI1007230A2 (pt) 2016-02-16
EP2381954B8 (en) 2017-01-25
CA2748873C (en) 2017-09-12
BRPI1007230B1 (pt) 2019-11-12
CL2011001769A1 (es) 2012-08-31
JP2012515551A (ja) 2012-07-12

Similar Documents

Publication Publication Date Title
US8969529B2 (en) Methods and compositions based on shiga toxin type 2 protein
US20130101591A1 (en) Methods and compositions based on shiga toxin type 1 protein
KR102960761B1 (ko) 스타필로코커스 오레우스(staphylococcus aureus) 류코톡신에 대한 항체
KR20100126760A (ko) 클로스트리듐 디피실레 포자에 대한 항체 및 그 용도
Chourasia et al. Delineation of immunodominant and cytadherence segment (s) of Mycoplasma pneumoniae P1 gene
Shekhar et al. Antibodies reactive to commensal Streptococcus mitis show cross-reactivity with virulent Streptococcus pneumoniae serotypes
Haque et al. Human B cell epitope map of the Lyme disease vaccine antigen, OspA
US9944694B2 (en) Antibodies against Staphylococcus aureus and uses therof
US20160075768A1 (en) Adjuvant therapy for staphylococcal infection with enterotoxin specific mabs
Davenport et al. The variable C-terminal region of the Mycobacterium leprae 70-kilodalton heat shock protein is the target for humoral immune responses
WO2019133799A1 (en) Monoclonal antibodies targeting microtubule-binding domain of tau protein
Megli et al. Crystal structure of the Vibrio cholerae colonization factor TcpF and identification of a functional immunogenic site
Farshad et al. Production and characterization of monoclonal antibodies against Brucella abortus S (99) surface antigens
Imani et al. Production and characterization of pertussis toxin specific monoclonal and polyclonal antibodies: Implication for toxin purification and detection
Fegan et al. Rational selection of TbpB variants elucidates a bivalent vaccine formulation with broad spectrum coverage against Neisseria gonorrhoeae
KR101905083B1 (ko) 비브리오 콜레라균 엠에이알티엑스 브이씨(martxvc) 단백질에 교차 결합하는 단일클론항체 및 이의 용도
KR101905095B1 (ko) 비브리오 콜레라균 엠에이알티엑스 브이씨(martxvc) 단백질에 교차 결합하는 단일클론항체 및 이의 용도
Chourasia et al. Delineation of immunodominant and
Huang et al. Prepared polyclonal antibody of the ciprofloxacin
Nguyen et al. The Structural Basis of Salmonella A 2 B 5 Neutralization by Antibodies Targeting the Glycan-Receptor Binding Subunits